The next 10 months might be challenging for this biotech.

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Shares of Puma Biotechnology PBYI have tanked 9.6% in the past month, reflecting the growing investor concern regarding the ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division a ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...